

King Pharmaceuticals, Inc.  
501 Fifth Street  
Bristol, Tennessee 37620



1-800-336-7783  
1-423-989-8001  
Fax: 1-423-989-6113

March 31, 2000

**Thomas K. Rogers, III, M.S.**  
*Vice President, Regulatory Affairs*

***AVAILABLE FOR PUBLIC DISCLOSURE WITHOUT REDACTION***

Mr. John Treacy  
Advisors and Consultants Staff (HFD-21)  
Food and Drug Administration  
Center for Drug Evaluation and Research  
5630 Fishers Lane  
Rockville, MD 20857

**Re: NDA 19-901/S028  
Altace® (ramipril) Capsules  
User Fee ID #: 3892  
Cardio-Renal Advisory Committee – Briefing Package**

Dear Mr. Treacy:

A Supplemental Application seeking approval of additional indications for Altace (ramipril) Capsules was submitted to FDA's Division of Cardio-Renal Drug Products on January 18, 2000. The Division Director, Dr. Raymond Lipicky, advised the firm that this submission will be considered by the Cardio-Renal Advisory Committee on May 1, 2000.

We are providing the enclosed Briefing Packages for distribution to members of the Committee and to FDA's reviewing Division. Under separate cover, we are also providing a copy of the package to Ms. Joan Standaert, Executive Secretary to the Committee. As indicated above, we believe that all of the materials provided herein are fully disclosable under the Freedom of Information Act.

The application is founded upon the results of the Heart Outcomes Prevention Evaluation (HOPE) Study conducted by the HOPE Study Investigators and reported in *The New England Journal of Medicine* and *The Lancet*. Briefing materials provided include a submission background, copies of the related published journal articles, study protocols, definitions for terms of adjudication, and proposed labeling as submitted to FDA.

Most of the documents included within the Briefing Package are also provided electronically on the accompanying disc. Please advise if you have questions or if we can be of further assistance in this matter.

Sincerely,  
KING PHARMACEUTICALS, INC.

Thomas K. Rogers, III  
Vice President Regulatory Affairs

2795 00 APR 20 P 2:39

## Table of Contents

### Section

- I. The HOPE Study Briefing Document
- II. Draft Labeling
- III. HOPE Event Adjudication Definitions
- IV. The HOPE Study Protocol
- V. 1/20/2000 - **The New England Journal of Medicine**  
*"Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients"*
- VI. 1/22/2000 - **The Lancet**  
*"Effects of Ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy"*
- VII. 1/20/2000 - **The New England Journal of Medicine**  
*"Vitamin B supplementation and cardiovascular events in high-risk patients"*
- VIII. 2/1996 - **Canadian Journal of Cardiology**  
*"The HOPE (Heart Outcomes Prevention Evaluation) Study: The design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (Ramipril) and vitamin E in patients at high risk of cardiovascular events"*